The H. Lee Moffitt Cancer Center and Research Institute has described cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammation and myotonic dystrophy type 1 disease.
Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic, hypertensive, HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis.
Cascade Pharmaceuticals Inc. has synthesized thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of MASLD/NAFLD, hypothyroidism and more.
Genzyme Corp. (dba Sanofi Genzyme) has disclosed isoxazolidine compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis, among others.
Investigators at Ileadbms Co. Ltd. have discovered a new cyclin-dependent kinase 12 (CDK12) and CDK13 inhibitor, IL6-110, which is being developed for the treatment of cancer.
Merck & Co. Inc. has announced plans to initiate clinical development of a new investigational multi-valent human papillomavirus (HPV) vaccine designed to provide broader protection against multiple HPV types.
Alterations in mitochondrial dynamics are hallmarks of Parkinson’s disease (PD) and other neurodegenerative disorders such as Alzheimer’s disease (AD).
RSS
